Larimar Therapeutics
LRMR
45 hedge funds and large institutions have $143M invested in Larimar Therapeutics in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 20 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 8
2.82% more ownership
Funds ownership: 91.81% → 94.63% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less funds holding
Funds holding: 57 → 45 (-12)
31% less capital invested
Capital invested by funds: $206M → $143M (-$63.3M)
40% less call options, than puts
Call options by funds: $6K | Put options by funds: $10K
60% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$8.22M |
| 2 |
DM
Deerfield Management
New York
|
+$7.75M |
| 3 |
Janus Henderson Group
London,
|
+$5.18M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.34M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$9.02M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.21M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.36M |
| 4 |
CCM
CAAS Capital Management
New York
|
-$3.2M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.8M |
LRMR Hedge Fund Activity: Q2 2021 in Review
45 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2021, worth a combined $143M — down 31% from $206M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of LRMR and 8 opened new positions — a net loss of 12 holders — while 8 trimmed existing stakes and 16 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $8.22M. The largest seller was OrbiMed, exiting entirely with an estimated $9.02M sold.
- 45 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2021, down from 57 in Q1 2021.
- Funds reported $143M of Larimar Therapeutics stock for Q2 2021, down 31% quarter-over-quarter.
- 8 funds opened new Larimar Therapeutics positions in Q2 2021 and 20 closed out, a net change of -12 holders.
- The largest Larimar Therapeutics buyer in Q2 2021 was Opaleye Management, an estimated $8.22M added.
- The largest Larimar Therapeutics seller in Q2 2021 was OrbiMed, an estimated $9.02M sold.
Based on aggregated 13F filings for Q2 2021.